Literature DB >> 9605156

Differential requirement for CD4 help in the development of an antigen-specific CD8+ T cell response depending on the route of immunization.

H Bour1, C Horvath, C Lurquin, J C Cerottini, H R MacDonald.   

Abstract

Previous studies in our laboratory have shown that DBA/2 mice injected i.p. with syngeneic P815 tumor cells transfected with the HLA-CW3 gene (P815-CW3) showed a dramatic expansion of activated CD8+CD62L- T cells expressing exclusively the Vbeta10 segment. We have used this model to study the regulatory mechanisms involved in the development of the CW3-specific CD8+ response, with respect to different routes of immunization. Whereas both intradermal (i.d.) and i.p. immunization of DBA/2 mice with P815-CW3 cells led to a strong expansion of CD8+CD62L-Vbeta10+ cells, only the i.d. route allowed this expansion after immunization with P815 cells transfected with a minigene coding for the antigenic epitope CW3 170-179 (P815 miniCW3). Furthermore, depletion of CD4+ T cells in vivo completely abolished the specific response of CD8+CD62L-Vbeta10+ cells and prevented the rejection of P815-CW3 tumor cells injected i.p., whereas it did not affect CD8S+CD62L-Vbeta10+ cell expansion after i.d. immunization with either P815-CW3 or P815 miniCW3. Finally, the CW3-specific CD8+ memory response was identical whether or not CD4+ T cells were depleted during the primary response. Collectively, these results suggest that the CD8+ T cell response to P815-CW3 tumor cells injected i.p. is strictly dependent upon recognition of a helper epitope by CD4+ T cells, whereas no such requirement is observed for i.d. injection.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605156

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

1.  In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses.

Authors:  Christoph Esslinger; Laurence Chapatte; Daniela Finke; Isabelle Miconnet; Philippe Guillaume; Frédéric Lévy; H Robson MacDonald
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

2.  A tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells.

Authors:  Mamoru Kawahara; Hiroshi Takaku
Journal:  Cancer Biol Ther       Date:  2015-09-21       Impact factor: 4.742

3.  Vaccination with lipid core peptides fails to induce epitope-specific T cell responses but confers non-specific protective immunity in a malaria model.

Authors:  Simon H Apte; Penny L Groves; Mariusz Skwarczynski; Yoshio Fujita; Chenghung Chang; Istvan Toth; Denise L Doolan
Journal:  PLoS One       Date:  2012-08-24       Impact factor: 3.240

4.  gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+T cells.

Authors:  L S Kierstead; E Ranieri; W Olson; V Brusic; J Sidney; A Sette; Y L Kasamon; C L Slingluff; J M Kirkwood; W J Storkus
Journal:  Br J Cancer       Date:  2001-11-30       Impact factor: 7.640

5.  Effect of B7.1 costimulation on T-cell based immunity against TAP-negative cancer can be facilitated by TAP1 expression.

Authors:  Xiao-Lin Li; Yong-Yu Liu; David Knight; Yoshinobu Odaka; J Michael Mathis; Runhua Shi; Jonathan Glass; Qian-Jin Zhang
Journal:  PLoS One       Date:  2009-07-24       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.